[go: up one dir, main page]

AU2008272330A1 - Anti-Muc17 antibody - Google Patents

Anti-Muc17 antibody Download PDF

Info

Publication number
AU2008272330A1
AU2008272330A1 AU2008272330A AU2008272330A AU2008272330A1 AU 2008272330 A1 AU2008272330 A1 AU 2008272330A1 AU 2008272330 A AU2008272330 A AU 2008272330A AU 2008272330 A AU2008272330 A AU 2008272330A AU 2008272330 A1 AU2008272330 A1 AU 2008272330A1
Authority
AU
Australia
Prior art keywords
antibody
muc17
cells
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008272330A
Other languages
English (en)
Inventor
Kiyotaka Nakano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forerunner Pharma Research Co Ltd
Original Assignee
Forerunner Pharma Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Research Co Ltd filed Critical Forerunner Pharma Research Co Ltd
Publication of AU2008272330A1 publication Critical patent/AU2008272330A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G01N33/5753—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008272330A 2007-07-04 2008-07-03 Anti-Muc17 antibody Abandoned AU2008272330A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007-176319 2007-07-04
JP2007176319 2007-07-04
PCT/JP2008/001777 WO2009004822A1 (fr) 2007-07-04 2008-07-03 ANTICORPS ANTI-Muc17

Publications (1)

Publication Number Publication Date
AU2008272330A1 true AU2008272330A1 (en) 2009-01-08

Family

ID=40225887

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008272330A Abandoned AU2008272330A1 (en) 2007-07-04 2008-07-03 Anti-Muc17 antibody

Country Status (7)

Country Link
US (1) US8546546B2 (fr)
EP (1) EP2172483A4 (fr)
JP (1) JP5938816B2 (fr)
CN (1) CN101687924A (fr)
AU (1) AU2008272330A1 (fr)
CA (1) CA2691734A1 (fr)
WO (1) WO2009004822A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5746018B2 (ja) * 2009-04-16 2015-07-08 国立大学法人 東京大学 抗ｔｍｐｒｓｓ１１ｅ抗体を用いた癌の診断と治療
US9119869B2 (en) * 2010-04-29 2015-09-01 Ronald J. Shebuski Mucin derived polypeptides
EP2589609A1 (fr) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Protéine se liant à un antigène et son utilisation pour l'adressage d'un produit pour le traitement du cancer
CA2871116A1 (fr) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions et methodes destinees a diagnostiquer et a traiter des tumeurs
EP3489261B1 (fr) 2012-08-24 2020-10-21 The Regents of The University of California Anticorps et vaccins pour utilisation dans le traitement de cancers ror1 et inhibition des métastases
US9907593B2 (en) 2014-08-05 2018-03-06 Woven Orthopedic Technologies, Llc Woven retention devices, systems and methods
US20180221059A1 (en) 2015-08-05 2018-08-09 Woven Orthopedic Technologies, Llc Tapping devices, systems and methods for use in bone tissue
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
EP3988111A1 (fr) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Utilisation de cellules modifiées par un récepteur d'antigène chimérique pour traiter le cancer
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
JP7137563B2 (ja) 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体
US11395681B2 (en) 2016-12-09 2022-07-26 Woven Orthopedic Technologies, Llc Retention devices, lattices and related systems and methods
UY38041A (es) * 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
AU2019208025A1 (en) 2018-01-11 2020-09-03 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
IL296601A (en) * 2020-03-19 2022-11-01 Amgen Inc Antibodies against mucin 17 and their uses
CA3194771A1 (fr) 2020-09-16 2022-03-24 Amgen Inc. Methodes d'administration de doses therapeutiques de molecules bispecifiques activant les lymphocytes t pour le traitement du cancer
WO2023066336A1 (fr) * 2021-10-21 2023-04-27 江苏先声药业有限公司 Nanocorps anti-muc17 et son utilisation
CN120603853A (zh) * 2023-02-03 2025-09-05 山东先声生物制药有限公司 针对muc17和cd3的双特异性抗体及其应用
CN118667026A (zh) * 2023-03-15 2024-09-20 三生国健药业（上海）股份有限公司 抗muc17*cd3*cd28三特异性抗体
CN117534750B (zh) * 2023-10-16 2024-06-11 遵义医科大学珠海校区 一种抗新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用
CN120554518A (zh) * 2024-02-28 2025-08-29 杭州中美华东制药有限公司 抗Mucin 17抗体、其偶联物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569919T3 (es) * 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US7078188B2 (en) * 2003-11-10 2006-07-18 Board Of Regents Of The University Of Nebraska MUC17 encoding nucleic acid sequences, polypeptides, antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN101687924A (zh) 2010-03-31
US20100240872A1 (en) 2010-09-23
JP5938816B2 (ja) 2016-06-22
EP2172483A4 (fr) 2010-08-04
WO2009004822A1 (fr) 2009-01-08
US8546546B2 (en) 2013-10-01
CA2691734A1 (fr) 2009-01-08
JPWO2009004822A1 (ja) 2010-08-26
EP2172483A1 (fr) 2010-04-07

Similar Documents

Publication Publication Date Title
US8546546B2 (en) Anti-Muc 17 antibody
AU2008321840B2 (en) Diagnosis and treatment of cancer using anti-GPR49 antibody
US10696743B2 (en) Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
EP2241578B1 (fr) Anticorps anti-cldn6
US9920129B2 (en) Diagnosis and treatment of cancer using anti-ITM2A antibody
US20100111852A1 (en) Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
CA2748990A1 (fr) Diagnostic et traitement du cancer a l'aide d'un anticorps anti-lgr7
US9079957B2 (en) Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
HK1157361B (en) Diagnosis and treatment of cancer using anti-gpr49 antibody
AU2014201680A1 (en) Diagnosis and treatment of cancer using anti-GPR49 antibody

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application